Cardium Therapeutics is a health sciences and regenerative medicine company strategizing to acquire and develop new and innovative bio-medical product opportunities that have definable pathways to commercialization, partnering, sale, or other economic monetizations. To avoid the risk of relying on the success of any single technology platform or product type, Cardium operates under a business model that allows for multiple opportunities and revenue channels.
Excellagen® is the company's lead commercial product - a topical gel for wound care management with FDA clearance for marketing and sale in the United States. Excellagen is used for the treatment of neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds, and is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.
Cardium's lead clinical development product candidate, Generx®, is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. Generx is designed to stimulate the growth of supplemental collateral blood vessels in the heart in order to enhance myocardial blood flow. Generx has progressed through four randomized, placebo-controlled clinical studies at more than 100 medical centers in the United States and Western Europe.
To Go Brands, acquired in October 2012, develops, markets, and sells dietary supplements through established regional and national retailers. The brand markets and sells a portfolio of more than 25 products including, nutraceutical powder mixes, supplements, and chews to support healthy lifestyles.
For more information, visit cardiumthx.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com